Xeltis Moves Toward European Commercial Launch After CE Mark for aXess Vascular Access Device

Xeltis advanced its transition from a clinical-stage medtech company to an early commercial player this week, following CE mark approval for its aXess hemodialysis vascular access conduit. The company is now preparing for European rollout, focusing on physician training, reimbursement engagement, and building commercial infrastructure.

The CE mark was granted in roughly 84 working days under the EU MDR framework, a comparatively rapid review attributed to extensive clinical data. Pivotal 12‑month trial results in 120 complex hemodialysis patients showed 79% secondary patency and a low patency‑related reintervention rate of 1.3 per patient‑year.

According to Xeltis, aXess reduced patency‑related reinterventions by about 60% versus standard grafts and 30% versus fistulas when compared with published benchmarks. Infection rates were also markedly lower than those typically seen with catheters and conventional grafts, suggesting potential for fewer complications and lower overall costs.

The device is based on Xeltis’s Restorex polymer platform, designed to enable the body to grow a “living” blood vessel as the implant is gradually absorbed. Additional support comes from earlier six‑month data, 24‑month first‑in‑human outcomes, and cases with more than four years of follow‑up, reinforcing the durability profile.

Xeltis highlighted new 12‑month, multicenter EU pivotal data and clinician feedback at the Charing Cross Symposium in London. Presentations by Dr. Augusto Ministro described ultrasound indications of progressive compliance, with the aXess conduit behaving increasingly like a native vessel rather than a prosthesis.

The company also reported strong audience interest in a session led by Prof. Frans Moll on next‑generation bioabsorbable conduits for bypass, underlining growing attention to regenerative vascular technologies. Similar enthusiasm was noted at the Dialysezugangs Symposium in Hamburg, where surgeons and nephrology specialists engaged with the aXess program.

Clinicians were particularly focused on the potential for aXess to reduce reintervention procedures and catheter dependence, alongside advantages such as early cannulation, short hemostasis time, and lower infection risk. These features may support adoption in high‑volume dialysis centers if validated in broader real‑world use.

For the company’s longer‑term outlook, successful European commercialization of aXess could validate the Restorex platform across additional indications, including coronary bypass surgery. Overall, the week marked a clear inflection point for Xeltis, with regulatory risk reduced and commercial execution emerging as the main driver of future performance.